Several organizations perform systematic reviews of the literature and develop guidelines or recommendations for the use of genomic technologies (e.g., applications that are based on DNA, gene expression, and RNA). [4] [5] [6] Because genomic technologies have the potential to influence many areas of health care, professional societies and guideline developers will increasingly be making recommendations about genomic applications; however, it is often unclear how various groups review evidence and develop guidelines for genomic applications. In 2005, the Centers for Disease Control and Prevention launched the Evaluation of Genomic Applications in Practice and Prevention Working Group 5 to develop a model process for the evaluation of genomic tests and other applications in transition from research to practice. For each clinical scenario, the Evaluation of Genomic Applications in Practice and Prevention Working Group uses a framework that evaluates analytic validity, clinical validity, clinical utility, and associated ethical, legal, and social implications (ACCE Framework). 6 Other systems, such as the Grading of Recommendations Assessment, Development and Evaluation approach, 7 hone in on types of outcomes in determining these measures. 7, 8 Identifying differences in evaluation approaches between various systems and groups may be a first step toward methods harmonization.
Because no single recommending group covers the entirety of the field of genomics, it will be important to achieve a broad-based consensus on the minimum elements needed for evidence synthesis and guideline development in genomics. Toward this objective, the Centers for Disease Control and Prevention Office of Public Health Genomics and the National Cancer Institute's Division of Cancer Control and Population Sciences held a workshop, "Comparing, Contrasting, and Demystifying Methods for Knowledge Synthesis and EvidenceBased Guideline Development in Genomic Medicine, " in March 2013. The aim of the workshop was to engage representatives from a broad range of groups with interest in clinical guidelines and to discuss the methods used in knowledge synthesis and evidence-based guideline development. Moreover, the workshop initiated a dialogue to compare these methods and to assess whether the existing approaches are consistent with the recommendations proposed in the IOM report. 4 The current article synthesizes the information gathered from the workshop's materials and discussions.
MEtHOds
The workshop included representatives from 35 organizations, 13 of which make genomic guidelines or recommendations (Supplementary Table S1 online).
Before their participation in the workshop, representatives from nine organizations were asked to respond to eight questions on behalf of their organization. Seven key components of guideline development derived from the IOM report framed the basis for the open-ended questions (Supplementary Table S2 online ). The objective was to gather information relating to the process of evidence-based guideline development. We compiled relevant information from the responses of the representatives ( Table 1; Supplementary Table S3 online). The full summary was shared with the participants before the meeting to facilitate discussion during the workshop.
The format of the workshop included presentations and group discussions. The presentations primarily focused on methods and conceptual frameworks used by various groups in formulating evidence-based guidelines and recommendations and included information about how and why the methods have evolved. Following presentations, there was a group discussion on similarities and differences in methods and processes for rating quality, confidence in the results, and magnitude of evidence.
sUMMARY OF AssEssMEnt And WORKsHOP disCUssiOns
Eight organizations that recommend genomic applications for use in clinical practice or coverage by insurers responded to the open-ended questions (summary in Overall, all eight organizations share core components that are integral to their respective guideline/recommendation development process. All have written policies to address group membership and to identify, prevent, and manage conflicts of interests. External review of recommendations/guidelines exists in all organizations. The use of systematic reviews to assess the strength of scientific evidence varies widely across the organizations, as do factors involved in assessing the robustness of the scientific evidence.
Each organization strives to ensure that the composition of its committee developing a specific guideline is multidisciplinary whenever possible. Many organizations work to balance the composition between content and methods experts specific to the topic under review. Identification of membership can be achieved via peer recommendations or through active recruitment of individuals with proven leadership and expertise in the field. Some organizations require that at least one representative on each committee be from the patient community.
Disclosure of conflicts of interest is mandatory across all organizations; however, the degree of acceptable conflicts of interest varies. The American Society of Clinical Oncologists, for example, stipulates that less than 50% of a guideline panel members, including the panel chair, may have conflicts of
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interest. Conversely, the American College of Medical Genetics and Genomics discloses that in case of rare diseases, conflicts of interest may be unavoidable and expert members may have commercial relationships to the genetic test they were tasked with evaluating; however, they commit to transparency and these conflicts are disclosed in any publication related to the guideline.
The use of systematic reviews to assess the robustness of the scientific evidence varies considerably across the organizations. The IOM report specifically defines systematic reviews as those that meet standards set by the IOM's Committee on Standards for Systematic Reviews of Comparative Effectiveness Research. 3 It is likely that some participating organizations may not necessarily comply with all elements of the IOM definition for systematic reviews, as in some cases systematic reviews may not be comprehensive enough to accurately summarize the field.
As anticipated, how the organizations rank the quality of evidence varies depending on the topic of focus. Some organizations appraise the quality of the evidence based on several factors, including the study design (e.g., randomized controlled trials (RCTs) and prospective cohort studies), the consistency of the estimated effects (i.e., heterogeneity), and the sample sizes. What constitutes a high level of evidence also varies between the organizations. For example, the gold standards of the American Society of Clinical Oncologists differ depending on the type of guideline being considered: for therapeutic guidelines, an RCT or meta-analysis of RCTs is considered top tier, whereas prospective cohort studies or retrospective analyses with identifiable control groups are used for prognostic guidelines. The Blue Cross Blue Shield Association and the Evaluation of Genomic Applications in Practice and Prevention Working Group require recommended technologies to demonstrate analytic validity, clinical validity, and clinical utility, and preferred study designs can differ for each of these evaluation components. 5 Some organizations categorize the level of evidence based on the consensus of the group, whereas others use systematic review in conjunction with expert review. Although all organizations have some form of an external review process, the processes vary between organizations. External reviews of guidelines may either be arranged internally or rely on peer reviews via journal submission, which acts as a surrogate for external review. The groups also vary widely in their approach to updating recommendations. Some groups have a systematic approach to revisit and update guidelines, whereas others rely on topics coming from members before updating. Genetic counselors + + + -+ + a (++) Denotes in-house systematic reviews; (+) denotes that the group suggests a systematic review be conducted by guideline authors if there are none recently published; (-) denotes that systematic reviews are generally not performed, although those conducted by others may be considered if available.
b (++) Denotes mandatory external review prior to publishing guideline; (+) denotes that external review primarily occurs through peer review for journal submission; (-) denotes that no external review is required.
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Brief report disCUssiOn
We convened the workshop to address an emerging need in the integration of genomics into clinical medicine. The workshop's primary purpose was to discuss the minimal elements needed to synthesize and develop evidence-based guidelines for genomic applications. There is particular urgency to enhance high-quality guideline development in genomic medicine, which is underscored by the rapid growth in the number of genomic applications that are clinically available. Recently, Clyne et al. 9 showed that in 1 year (May 2012-April 2013), 45 clinical guidelines, policies, and recommendations were published for genomic applications (7 not published in PubMed). Comparisons of specific genomic guidelines using the AGREE II instrument, 10 as well as a recent review of grading systems used in the evaluation of genomic tests, 11 highlight the fact that there are no universal principles shared by organizations evaluating genomic applications.
The IOM report 3 specified key components that should be incorporated into the process of developing evidence-based guidelines/recommendations. When these processes were compared with the IOM report recommendations, the organizations that participated in the workshop agreed that the components that are integral to guideline/recommendation development are to establish policies to manage group membership and to identify, prevent, and manage conflicts of interest. However, the level of external review, updating of recommendations, and the use of systematic review to assess the strength of scientific evidence varied widely across the organizations. It should be noted that a group's ability to perform detailed systematic reviews may depend on the group's size and resources. However, some groups, such as the American College of Medical Genetics and Genomics, are now considering how their guideline development process could be more in line with the IOM report.
Guidelines from some organizations, such as the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group, assume that the genetic test information is already available and gear their recommendations toward how to use genomic information, not whether to order genetic tests. 12 The American College of Medical Genetics and Genomics has recently addressed this topic by putting forward a set of recommendations for the return of incidental findings in the setting of clinical whole-genome/whole-exome sequencing. 13 In addition, the National Institutes of Health is funding the Clinical Variant resource (ClinVar 14 ) and the clinically relevant genomics consortium (ClinGen) to develop standardized processes by which genomic variants are determined to be clinically relevant and actionable. 15 Given the rapidly changing landscape in genomic medicine, we may need more nimble methods and approaches to evidence-based guideline development than those currently used in other fields. For example, professional groups developing guidelines and recommendations could collaborate on a periodic basis and better leverage prior efforts in order to minimize the possibility of reinventing guidelines from scratch. Given their labor-intensive nature, systematic reviews could be conducted in a more coordinated manner. Groups could deposit systematic review data into the established Systematic Review Data Repository of the Agency for Healthcare Research and Quality, which could facilitate updating genomic-based recommendations more quickly. 16 The application of systematic, but rapid, methodologies may also be explored. 17 Groups such as the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group could coordinate much of their evidence review using annotation tools provided by the Pharmacogenomics Knowledge Base. 18 Professional groups should also continue the dialogue on balancing the need for evidence from observational studies versus RCTs. Observational evidence is frequently necessary, and RCTs are often not feasible, particularly in the case of rare diseases. Nevertheless, the need for RCTs may be unavoidable for some applications, a subject worthy of additional conversation. 19 Guideline developers will also need to consider the use of modeling to fill evidence gaps. 20 As is true for many clinical practice areas, and given the nascent state of the field, the process of guideline development in genomic medicine is unlikely to be entirely consistent with the IOM recommendations. Although one size does not fit all, and genomics may not be currently able to meet all of the IOM report's requirements, genomic guideline developers should strive to incorporate as many of the IOM report recommendations as possible for successful evidence-based implementation of genomic medicine in practice.
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